C
Cheryl A. London
Researcher at University of California, Davis
Publications - 30
Citations - 3664
Cheryl A. London is an academic researcher from University of California, Davis. The author has contributed to research in topics: Cytotoxic T cell & T cell. The author has an hindex of 24, co-authored 30 publications receiving 3495 citations. Previous affiliations of Cheryl A. London include Brigham and Women's Hospital & Harvard University.
Papers
More filters
Journal ArticleDOI
Biochemical Mechanisms of IL-2–Regulated Fas-Mediated T Cell Apoptosis
TL;DR: The ability of IL-2 to enhance expression of a pro-apoptotic molecule, FasL, and to suppress an inhibitor of Fas signaling, FLIP, likely accounts for the role of this cytokine in potentiating T cell apoptosis.
Journal ArticleDOI
Functional Responses and Costimulator Dependence of Memory CD4+ T Cells
TL;DR: The findings suggest that the threshold for activation of memory CD4+ cells is lower than that of naive cells, which would permit memory cells to rapidly express their effector functions in vivo earlier in the course of a secondary immune response, when the levels of Ag and the availability of costimulation may be relatively low.
Journal ArticleDOI
Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision
Cheryl A. London,Phyllis B. Malpas,Stacey L. Wood-Follis,Joseph F. Boucher,Anthony Rusk,Mona P. Rosenberg,Carolyn J. Henry,Kathy L. Mitchener,Mary K. Klein,John G. Hintermeister,Philip J. Bergman,Guillermo Couto,Guy N. Mauldin,Gina M. Michels +13 more
TL;DR: Palladia has biological activity against canine MCTs and can be administered on a continuous schedule without need for routine planned treatment breaks, and shows that spontaneous tumors in dogs are good models to evaluate therapeutic index of targeted therapeutics in a clinical setting.
Journal Article
Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosine Kinase Inhibitor, in Dogs with Spontaneous Malignancies,
Cheryl A. London,Alison L. Hannah,Regina Zadovoskaya,May B. Chien,Cynthia Kollias-Baker,Mona P. Rosenberg,Sue Downing,G. S. Post,Joseph F. Boucher,Narmada Shenoy,Dirk B. Mendel,Gerald McMahon,Julie M. Cherrington +12 more
TL;DR: This study provides the first evidence that p.o. administered kinase inhibitors can exhibit activity against a variety of spontaneous malignancies in dogs, and it is likely that such agents will demonstrate comparable antineoplastic activity in people.
Journal ArticleDOI
Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.
Cheryl A. London,Cheryl A. London,Stephen J. Galli,Toshifumi Yuuki,Zhi-Qing Hu,Stuart C. Helfand,Edwin N. Geissler +6 more
TL;DR: It is demonstrated that although c-kit derived from canine MCT did not contain the previously described activating point mutations, 5 of the 11 tumors analyzed possessed novel mutations consisting of tandem duplications involving exons 11 and 12, suggesting that these mutations may contribute to the development or progression of canine M CT.